Vascular endothelial growth factor D (VEGF-D)

Vascular endothelial growth factor D (VEGF-D) is an important growth factor for in angiogenesis, lymphangiogenesis, and endothelial cell growth. It stimulates endothelial cell proliferation and migration and also has effects on the permeability of blood vessels. It may function in the formation of the venous and lymphatic vascular systems during embryogenesis and in the maintenance of differentiated lymphatic endothelium in adults. VEGF-D binds and activates VEGFR-2 (Flk1) and VEGFR-3 (Flt4) receptors. It is a homodimer, highly expressed in lung, heart, small intestine and fetal lung; and at lower levels in skeletal muscle, colon, and pancreas. It undergoes a complex proteolytic maturation which generates a variety of processed secreted forms with increased activity toward VEGFR-3 and VEGFR-2. VEGF-D first forms an antiparallel homodimer linked by disulfide bonds before secretion. The fully processed VEGF-D is composed mostly of two VEGF homology domains (VHDs) bound by non-covalent interactions.

Swiss-Prot Accession Number: O43915


Myriad RBM Publications Publications
Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment (2018) van den Ham HJ, Cooper J, Tomasik J, Bahn S, Aerts J, Oseterhaus A, Gruters R, Andeweg A PLoS One
Circulating biomarkers from the phase I trial of sirolimus and autophagy inhibition for patients with lymphangioleiomyomatosis (SAIL). (2018) Lamattina AM, Taveira-Dasilva A, Goldberg HJ, Bagwe S, Cui Y, Rosas IO, Moss J, Henske EP, El-Chemaly S Chest Journal
Complexity of Macrophage Migration Inhibitory Factor (MIF) and Other Angiogenic Biomarkers Profiling in Pulmonary Arterial Hypertension. (2017) Marshall JD, Sauler M, Tonelli A, Rao Y, Bucala R, Lee P, Fares W Pulm Circ.
Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib. (2014) Pommier AJ, Shaw R, Spencer SK, Morgan SR, Hoff PM, Robertson JD, Barry ST, Jürgensmeier JM. British Journal of Cancer 2014 Aug 14. doi: 10.1038/bjc.2014.436. [Epub ahead of print]
Impact of Sunitinib on Human Thyroid Cancer Cells (2013) Grosse J, Warnke E, Pohl F, Magnusson NE, Wehland M, Infanger M, Eilles C, Grimm D Cell Physiol Biochem. 2013 Jul 12;32(1):154-170
Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy (2013) Spencer SK, Pommier AJ, Morgan SR, Barry ST, Robertson JD, Hoff PM, Jürgensmeier JM Br J Cancer. 2013 Oct 22
Differential gene expression profile and altered cytokine secretion of thyroid cancer cells in space (2013) Ma X, Pietsch J, Wehland M, Schulz H, Saar K, Hübner N, Bauer J, Braun M, Schwarzwälder A, Segerer J, Birlem M, Horn A, Hemmersbach R, Waßer K, Grosse J, Infanger M, Grimm D FASEB J. 2013 Nov 6. [Epub ahead of print]
Blood profiling of proteins and steroids during weight maintenance with manipulation of dietary protein level and glycaemic index (2012) Wang P, Holst C, Astrup A, Bouwman FG, van Otterdijk S, Wodzig WK, Andersen MR, van Baak MA, Rasmussen LG, Martinez JA, Jebb SA, Pfeiffer AF, Kafatos A, Handjieva-Darlenska T, Hlavaty P, Saris WH, Mariman EC Br J Nutr. 2012 Jan;107(1):106-19